115 related articles for article (PubMed ID: 35245832)
1. PD-1 and TIGIT blockade differentially affect tumour cell survival under hypoxia and glucose deprived conditions in oesophageal adenocarcinoma; implications for overcoming resistance to PD-1 blockade in hypoxic tumours.
Davern M; Fitzgerald MC; Buckley CE; Heeran AB; Donlon NE; McGrath J; O' Connell F; Deshpande MR; Hayes C; MacDonald J; Sheppard AD; Reynolds JV; Maher SG; Lynam-Lennon N; Murphy B; Lysaght J
Transl Oncol; 2022 May; 19():101381. PubMed ID: 35245832
[TBL] [Abstract][Full Text] [Related]
2. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells.
Davern M; Donlon NE; Sheppard A; Connell FO; Hayes C; Bhardwaj A; Foley E; Toole DO; Lynam-Lennon N; Ravi N; Reynolds JV; Maher SG; Lysaght J
Transl Oncol; 2021 Jun; 14(6):101062. PubMed ID: 33765543
[TBL] [Abstract][Full Text] [Related]
4. PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma.
Davern M; O' Brien RM; McGrath J; Donlon NE; Melo AM; Buckley CE; Sheppard AD; Reynolds JV; Lynam-Lennon N; Maher SG; Lysaght J
Sci Rep; 2022 Feb; 12(1):3259. PubMed ID: 35228614
[TBL] [Abstract][Full Text] [Related]
5. Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.
Donlon NE; Davern M; O'Connell F; Sheppard A; Heeran A; Bhardwaj A; Butler C; Narayanasamy R; Donohoe C; Phelan JJ; Lynam-Lennon N; Dunne MR; Maher S; O'Sullivan J; Reynolds JV; Lysaght J
World J Gastroenterol; 2022 Jun; 28(21):2302-2319. PubMed ID: 35800186
[TBL] [Abstract][Full Text] [Related]
6. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
[TBL] [Abstract][Full Text] [Related]
7. Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib.
Buckley AM; Dunne MR; Morrissey ME; Kennedy SA; Nolan A; Davern M; Foley EK; Clarke N; Lysaght J; Ravi N; O'Toole D; MacCarthy F; Reynolds JV; Kennedy BN; O'Sullivan J
Sci Rep; 2020 Jul; 10(1):12105. PubMed ID: 32694701
[TBL] [Abstract][Full Text] [Related]
8. Expression of neuroepithelial transforming gene 1 is enhanced in oesophageal cancer and mediates an invasive tumour cell phenotype.
Lahiff C; Cotter E; Casey R; Doran P; Pidgeon G; Reynolds J; Macmathuna P; Murray D
J Exp Clin Cancer Res; 2013 Aug; 32(1):55. PubMed ID: 23945136
[TBL] [Abstract][Full Text] [Related]
9. Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma.
Belle CJ; Lonie JM; Brosda S; Barbour AP
Front Immunol; 2023; 14():1330635. PubMed ID: 38155973
[TBL] [Abstract][Full Text] [Related]
10. Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal Adenocarcinoma.
Melo AM; O'Brien AM; Phelan JJ; Kennedy SA; Wood NAW; Veerapen N; Besra GS; Clarke NE; Foley EK; Ravi A; MacCarthy F; O'Toole D; Ravi N; Reynolds JV; Conroy MJ; Hogan AE; O'Sullivan J; Dunne MR
Front Immunol; 2019; 10():1580. PubMed ID: 31354725
[TBL] [Abstract][Full Text] [Related]
11. Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; Habash M; Sheppard AD; MacLean M; Dunne MR; Moore J; Temperley H; Conroy MJ; Butler C; Bhardwaj A; Ravi N; Donohoe CL; Reynolds JV; Lysaght J
Cancer Immunol Immunother; 2023 Jan; 72(1):55-71. PubMed ID: 35708739
[TBL] [Abstract][Full Text] [Related]
12. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.
Hung AL; Maxwell R; Theodros D; Belcaid Z; Mathios D; Luksik AS; Kim E; Wu A; Xia Y; Garzon-Muvdi T; Jackson C; Ye X; Tyler B; Selby M; Korman A; Barnhart B; Park SM; Youn JI; Chowdhury T; Park CK; Brem H; Pardoll DM; Lim M
Oncoimmunology; 2018; 7(8):e1466769. PubMed ID: 30221069
[TBL] [Abstract][Full Text] [Related]
13. Dietary inflammatory index and risk of reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma: a population-based case-control study.
Shivappa N; Hebert JR; Anderson LA; Shrubsole MJ; Murray LJ; Getty LB; Coleman HG
Br J Nutr; 2017 May; 117(9):1323-1331. PubMed ID: 28571591
[TBL] [Abstract][Full Text] [Related]
14. CD155T/TIGIT Signaling Regulates CD8
He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous blockade of TIGIT and HIF-1α induces synergistic anti-tumor effect and decreases the growth and development of cancer cells.
Fathi M; Bahmanpour S; Barshidi A; Rasouli H; Karoon Kiani F; Mahmoud Salehi Khesht A; Izadi S; Rashidi B; Kermanpour S; Mokhtarian R; Karpisheh V; Hassannia H; Mohammadi H; Jalili A; Jadidi-Niaragh F
Int Immunopharmacol; 2021 Dec; 101(Pt A):108288. PubMed ID: 34710844
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers.
Hosseinkhani N; Shadbad MA; Asghari Jafarabadi M; Karim Ahangar N; Asadzadeh Z; Mohammadi SM; Lotfinejad P; Alizadeh N; Brunetti O; Fasano R; Silvestris N; Baradaran B
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638729
[TBL] [Abstract][Full Text] [Related]
17. Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma.
Davern M; Donlon NE; O' Connell F; Sheppard AD; Hayes C; King R; Temperley H; Butler C; Bhardwaj A; Moore J; Bracken-Clarke D; Donohoe C; Ravi N; Reynolds JV; Maher SG; Conroy MJ; Lysaght J
Transl Oncol; 2022 Jun; 20():101406. PubMed ID: 35366537
[TBL] [Abstract][Full Text] [Related]
18. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
[TBL] [Abstract][Full Text] [Related]
19. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
Front Immunol; 2021; 12():699895. PubMed ID: 34367161
[TBL] [Abstract][Full Text] [Related]
20. Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.
Kastelein F; van Olphen SH; Steyerberg EW; Spaander MC; Bruno MJ;
Gut; 2016 Apr; 65(4):548-54. PubMed ID: 25903690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
